AR116026A1 - Composición para erradicar helicobacter pylori - Google Patents

Composición para erradicar helicobacter pylori

Info

Publication number
AR116026A1
AR116026A1 ARP190102443A ARP190102443A AR116026A1 AR 116026 A1 AR116026 A1 AR 116026A1 AR P190102443 A ARP190102443 A AR P190102443A AR P190102443 A ARP190102443 A AR P190102443A AR 116026 A1 AR116026 A1 AR 116026A1
Authority
AR
Argentina
Prior art keywords
helicobacter pylori
composition
formula
pharmaceutically acceptable
compound represented
Prior art date
Application number
ARP190102443A
Other languages
English (en)
Spanish (es)
Inventor
Haneul Jeong
Yu Park
- Kim Jae Min Gyeong
Hyun Ji Kang
Naree Shin
Eun Kyung Kim
Shi Ryu
- Song Geun Seog Young
Ahrong Kim
Kyeongmin Oh
Ji Won Lee
Eun Ji Kim
Dongkyu Kim
Bong Tae Kim
Original Assignee
Hk Inno N Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hk Inno N Corp filed Critical Hk Inno N Corp
Publication of AR116026A1 publication Critical patent/AR116026A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ARP190102443A 2018-08-29 2019-08-28 Composición para erradicar helicobacter pylori AR116026A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20180102250 2018-08-29

Publications (1)

Publication Number Publication Date
AR116026A1 true AR116026A1 (es) 2021-03-25

Family

ID=69643254

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102443A AR116026A1 (es) 2018-08-29 2019-08-28 Composición para erradicar helicobacter pylori

Country Status (28)

Country Link
US (2) US20210196685A1 (enExample)
EP (1) EP3843723B1 (enExample)
JP (1) JP7189327B2 (enExample)
KR (1) KR20200026118A (enExample)
CN (1) CN112638378A (enExample)
AR (1) AR116026A1 (enExample)
AU (1) AU2019328903B2 (enExample)
CA (1) CA3107624C (enExample)
DK (1) DK3843723T3 (enExample)
EA (1) EA202190622A1 (enExample)
ES (1) ES3060114T3 (enExample)
FI (1) FI3843723T3 (enExample)
GE (2) GEP20227431B (enExample)
HR (1) HRP20260170T1 (enExample)
JO (1) JOP20190201B1 (enExample)
LT (1) LT3843723T (enExample)
MX (1) MX2021002278A (enExample)
MY (1) MY195494A (enExample)
PH (1) PH12021550385A1 (enExample)
PL (1) PL3843723T3 (enExample)
PT (1) PT3843723T (enExample)
RS (1) RS67791B1 (enExample)
SG (1) SG11202101920WA (enExample)
SI (1) SI3843723T1 (enExample)
SM (1) SMT202600153T1 (enExample)
UA (1) UA126993C2 (enExample)
UY (1) UY38348A (enExample)
WO (1) WO2020045992A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CA3132575A1 (en) * 2019-04-18 2020-10-22 Thomas Julius Borody Compositions and methods for treating, ameliorating and preventing h. pylori infections
WO2024210689A1 (ko) * 2023-04-07 2024-10-10 제이더블유중외제약 주식회사 벤즈이미다졸 유도체의 염
TW202535382A (zh) * 2023-11-29 2025-09-16 南韓商第一藥品股份有限公司 包含ｚａｓｔａｐｒａｚａｎ或其醫藥上可接受的鹽之用於幽門螺旋桿菌根除的組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753324B2 (en) * 1998-07-15 2004-06-22 Hassan Jomaa Phosphorous organic compounds and their use
WO2007072146A1 (en) 2005-12-19 2007-06-28 Pfizer Japan Inc. Chromane substituted benzimidazoles and their use as acid pump inhibitors
CN101015694A (zh) * 2006-02-07 2007-08-15 沈阳东宇药业有限公司 一种治疗幽门螺旋杆菌感染的复方口服制剂
MA41730B1 (fr) * 2015-06-08 2019-03-29 Cj Healthcare Corp Utilisation de dérivé de benzimidazole pour l'acidité nocturne
US11096948B2 (en) * 2016-01-21 2021-08-24 Dexcel Pharma Technologies Ltd. Methods for treating helicobacter infection
KR101829706B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 산부가염
CN108379258B (zh) * 2017-11-30 2020-02-18 中国医学科学院医药生物技术研究所 瑞香素在抗幽门螺杆菌中的应用

Also Published As

Publication number Publication date
JP2021535910A (ja) 2021-12-23
JP7189327B2 (ja) 2022-12-13
KR20200026118A (ko) 2020-03-10
US20210196685A1 (en) 2021-07-01
JOP20190201A1 (ar) 2020-02-29
UY38348A (es) 2020-03-31
EP3843723A1 (en) 2021-07-07
WO2020045992A1 (en) 2020-03-05
CA3107624A1 (en) 2020-03-05
BR112021003578A2 (pt) 2021-05-18
MX2021002278A (es) 2021-08-11
GEAP202215593A (en) 2022-07-11
EA202190622A1 (ru) 2021-06-10
LT3843723T (lt) 2026-03-25
HRP20260170T1 (hr) 2026-05-08
SI3843723T1 (sl) 2026-04-30
EP3843723A4 (en) 2022-06-29
ES3060114T3 (enExample) 2026-03-25
SMT202600153T1 (it) 2026-05-12
US20250241897A1 (en) 2025-07-31
EP3843723B1 (en) 2026-01-07
RS67791B1 (sr) 2026-03-31
JOP20190201B1 (ar) 2024-04-18
AU2019328903A1 (en) 2021-04-29
DK3843723T3 (da) 2026-02-09
PT3843723T (pt) 2026-01-27
CA3107624C (en) 2023-10-03
CN112638378A (zh) 2021-04-09
UA126993C2 (uk) 2023-03-01
GEP20227431B (en) 2022-10-25
AU2019328903B2 (en) 2023-01-05
PL3843723T3 (pl) 2026-06-08
PH12021550385A1 (en) 2021-09-20
MY195494A (en) 2023-01-26
AU2019328903A8 (en) 2021-05-27
FI3843723T3 (fi) 2026-02-12
SG11202101920WA (en) 2021-04-29

Similar Documents

Publication Publication Date Title
CL2023003041A1 (es) Derivados de triazina que tienen actividad inhibidora de la replicación del virus y composición farmacéutica
MX2022010040A (es) Compuestos moduladores de gcn2.
CL2020000747A1 (es) Formulaciones de niraparib.
UY37845A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
CO2021005070A2 (es) Inhibición de la proteasa 30 específica de la ubiquitina (usp30)
MX2015016971A (es) Formulacion que comprende un agente hipolipidemico.
CL2017002936A1 (es) Compuestos ciclooctadepsipéptidos, composición veterinaria antihelmíntica, y uso para preparar un medicamento útil contra infección por parásitos o una infestación por parásitos internos o externos en un animal.
ECSP088412A (es) Derivados de pirazina como moduladores de canal de sodio en el tratamiento del dolor
AR053162A1 (es) Compuesto 5 - oxo - pirrolidin sustituido, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento del glaucoma.
MX358961B (es) Compuestos de tetraciclina sustituidos con fluor en c7.
AR090712A1 (es) Agentes para tratar trastornos que implican la modulacion de receptores de rianodina
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
ECSP14013200A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
CL2012001162A1 (es) Uso de compuestos derivados de acido tetramico para preparar composiciones contra plagas de insectos y/o acaros y/o nematodos mediante aplicacion del principio activo por goteo sobre el suelo.
UY38348A (es) Composición para erradicar helicobacter pylori
MX374295B (es) Sal de maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus métodos de preparación y usos de la sal de maleato y formas cristalinas.
AR134204A1 (es) Nuevos compuestos como moduladores de los canales de sodio y usos de los mismos
MX2024015493A (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1
MX2022012575A (es) Compuestos para usarse para tratar la enfermedad de huntington.
UY38345A (es) Composición farmacéutica que comprende agente antiplaquetario e inhibidor de la secreción de ácido g
SA521421354B1 (ar) مركبات مفيدة في صورة مُعدِّلات الالتهام الذاتي الذي تتوسط فيه شابرون
EP3998057A4 (en) COSMETIC COMPOSITION WITH GRAPHENE QUANTUM DOTS AS AN ACTIVE INGREDIENT
AR114418A1 (es) Compuesto cíclico de metilactama y su utilización farmacéutica
DOP2024000001A (es) Composición nematicida
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.

Legal Events

Date Code Title Description
FB Suspension of granting procedure